Shareholders of Tate & Lyle have accepted Ingredion's recommended all-cash offer for the entire issued share capital of the company, a milestone toward creating one of the largest global ingredient-solutions groups.
Under the terms first announced on June 8, 2026, Tate & Lyle shareholders will receive 595 pence in cash per share, with total cash consideration of approximately £2.7 billion, or about $3.6 billion at the exchange rate prevailing when the deal was struck.
Ingredion, based in Westchester, Illinois, reported approximately $7.2 billion in net sales in 2025 and supplies ingredients across the food, beverage, pharmaceutical, personal care and industrial sectors.
Tate & Lyle is a UK-based supplier specializing in mouthfeel, sweetening and fortification ingredients.
Ingredion expects the combined company to generate run-rate net cost synergies of approximately $130 million by the end of 2030, along with adjusted earnings-per-share accretion for Ingredion shareholders in the first year after completion.
Closing is expected in the second half of 2027, subject to regulatory clearance under the UK City Code on Takeovers and Mergers, meaning the deal still faces more than a year of antitrust and competition review before it can close.
Boards in the food and beverage supply chain should read the long runway to closing as typical for a cross-border ingredients combination of this size rather than a sign of regulatory difficulty.
The transaction fits a broader pattern of consolidation among specialty-ingredients suppliers, as manufacturers of packaged food and beverages seek fewer, larger partners capable of formulation support across multiple product categories and geographies.
For corporate boards in adjacent consumer categories, the deal is a reminder that scale in ingredient sourcing and formulation science is becoming a competitive differentiator that smaller regional suppliers will struggle to match.
It also illustrates how UK-listed companies with strong niche technology, such as Tate & Lyle's sweetening and fortification expertise, remain attractive acquisition targets for larger U.S.-based strategics with international ambitions.
Directors should watch the regulatory review process over the coming months for any required divestitures, and monitor whether the announced synergy targets hold up as integration planning begins ahead of the expected 2027 close.
The Boardroom Report · Published by Tetmo Publishing
Subscribe · Group pricing available